Guardant Health (DE:5GH)
NASDAQ:5GH
5GH Stock Chart & Stats
€72.40
€0.62(1.81%)
At close: 4:00 PM EST
€72.40
€0.62(1.81%)
Day’s Range― - ―
52-Week Range€35.65 - €122.16
Previous CloseN/A
Volume0.00
Average Volume (3M)34.00
Market Cap
€16.68B
Enterprise Value€17.84B
Total Cash (Recent Filing)€1.10B
Total Debt (Recent Filing)€1.70B
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Jul 30, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding132,599,930
10 Day Avg. Volume25
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€129.07Price Target Upside78.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-2.56
Revenue Forecast (FY)€1.16B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Raised GuidanceGuardant shows durable top-line momentum with TTM revenue near $1.08B and management raising 2026 guidance to $1.30–$1.32B. Revenue breadth across Oncology, Biopharma and Screening reflects diversified demand that supports multi-year scaling independent of short-term cycles.
Improving Gross Margins Via Sequencing Cost CutsStructural margin improvement stems from technology-led cost reductions (NovaSeq X) and scale, delivering ~66% gross margin in Q1 and guided FY margins near 64–65%. Lower per-test sequencing costs and Shield margin gains create sustainable unit economics as volumes continue to scale.
Large Data Assets, AI Platform And PartnershipsA >1M-sample data treasury plus InfinityAI and an expanding CDx footprint create durable competitive advantage for clinical validation, RWE generation and partner lock‑ins. Strategic biopharma collaborations and regulatory approvals reinforce long-term commercialization and product differentiation.
Bears Say
High Leverage And Negative EquityGuardant's elevated leverage and negative equity materially weaken balance-sheet resilience. High debt increases refinancing and covenant risk and limits strategic flexibility until sustained profitability or equity improvement reduces leverage metrics over time.
Persistent Negative Operating And Free Cash FlowThe business still consumes cash: TTM operating cash flow and FCF are deeply negative despite improvement. Achieving company-wide cash-flow breakeven by end-2027 depends on continued volume growth, reimbursement progress and tight expense execution; failure would prolong financing needs.
Reimbursement/regulatory Uncertainty And Heavy ReinvestmentGrowth relies on reimbursement wins and regulatory outcomes that remain pending (MolDx, ACS inclusion). Management is also materially increasing S&M and operating spend to scale Shield, which raises execution risk: delayed coverage or slower adoption would extend cash burn and depress margins.
Guardant Health News
5GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was €35.65 and its highest was €122.16 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is €16.68B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Jul 30, 2026 which is in 33 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 07, 2026. The company reported -€0.748 earnings per share for the quarter, missing the consensus estimate of -€0.709 by -€0.039.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.66.
How many shares outstanding does Guardant Health have?
Guardant Health has 132,599,930 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -€0.748 in its last earnings report, missing expectations of -€0.709. Following the earnings report the stock price went up 2.252%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in DE:5GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€129.07 (78.28% Upside)
€129.07 (78.28% Upside)
Blogger Sentiment
Bullish
DE:5GH Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €46.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.97%
12-Months-Change
Fundamentals
Return on Equity
184.27%
Trailing 12-Months
Asset Growth
42.48%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
5GH Company Deck
5GH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and commercial quarter: revenue growth was robust across Oncology, Biopharma & Data and Screening, Shield showed breakout traction with meaningful margin improvement, and product and data investments (InfinityAI, NovaSeq X transition, expanded FDA approvals and partnerships) support multi-year upside. Key near-term challenges include elevated operating expenses to fund growth, ongoing adjusted losses and free cash flow burn, and dependencies on reimbursement and third-party regulatory outcomes (MolDx reviews, drug approvals) that introduce timing and upside uncertainty. Overall, positives (accelerating revenue, volume, margin improvement, data/AI progress, and strengthened partnerships) materially outweigh the risks, though execution and reimbursement milestones remain important to sustain momentum.View all DE:5GH earnings summaries5GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
5GH Stock 12 Month Forecast
Average Price Target
€129.07
▲(78.28% Upside)
Technical Analysis
Options Prices
Currently, No data available
---